Company Description
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa.
The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.
It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services.
The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies.
The company markets and distributes its products directly to customers, as well as through life-science distributors.
Illumina, Inc. was incorporated in 1998 and is headquartered in San Diego, California.
| Country | United States |
| Founded | 1998 |
| IPO Date | Jul 28, 2000 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 10,370 |
| CEO | Jacob Thaysen |
Contact Details
Address: 5200 Illumina Way San Diego, California 92122 United States | |
| Phone | 858 202 4500 |
| Website | illumina.com |
Stock Details
| Ticker Symbol | ILMN |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001110803 |
| CUSIP Number | 452327109 |
| ISIN Number | US4523271090 |
| Employer ID | 33-0804655 |
| SIC Code | 3826 |
Key Executives
| Name | Position |
|---|---|
| Jacob Thaysen Ph.D. | Chief Executive Officer and Director |
| Kevin Carl Pegels | Chief of Global Operations |
| Dr. Steven Barnard Ph.D. | Chief Technology Officer |
| Stephanie Campos | President |
| Scott Ericksen | Vice President and Chief Accounting Officer |
| Brian Blanchett | Vice President of Finance and Treasurer and Interim Head of Investor Relations |
| Scott Davies | Chief Legal Officer |
| Jakob Wedel | Chief Strategy and Corporate Development Officer |
| Patricia Leckman | Senior Vice President and Chief People Officer |
| Todd P. Christian | Head of Services, Arrays and Genomics Access |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 16, 2025 | DEFR14A | Filing |
| Apr 9, 2025 | ARS | Filing |
| Apr 9, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 9, 2025 | DEF 14A | Other definitive proxy statements |
| Mar 25, 2025 | 8-K | Current Report |
| Mar 24, 2025 | 8-K | Current Report |
| Mar 10, 2025 | 8-K | Current Report |
| Feb 27, 2025 | 144 | Filing |
| Feb 18, 2025 | 144 | Filing |
| Feb 18, 2025 | 144 | Filing |